FindTrial
Sign In

RIC regimen

DRUG2 trials

Sponsors

Washington University School of Medicine, University Hospital Tuebingen

Conditions

AML (Acute Myeloid Leukemia)Bone Marrow Failure SyndromesHemoglobinopathiesImmunologic DisordersMDS (Myelodysplastic Syndrome)MDS/AMLMetabolic DisordersNon-malignant Disorders

Phase 1

Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
RecruitingNCT03128996
Washington University School of MedicineBone Marrow Failure Syndromes, Hemoglobinopathies, Immunologic Disorders +3
Start: 2017-03-20End: 2033-04-01Target: 29Updated: 2026-05-29

Phase 2

Venetoclax- Augmented Treosulfan-Based Reduced Intensity Conditioning Before Allogeneic Stem Cell Transplantation
Not yet recruitingNCT07214064
University Hospital TuebingenAML (Acute Myeloid Leukemia), MDS/AML, MDS (Myelodysplastic Syndrome)
Start: 2026-01-31End: 2027-12-31Target: 27Updated: 2025-10-09

Related Papers

Abatacept-Prophylaxis Based Haploidentical Transplantation May Allow Sustained Engraftment and Offset Gvhd in Non-Malignant Disorders
Blood2023-11-02
Abatacept is effective as GVHD prophylaxis in unrelated donor stem cell transplantation for children with severe sickle cell disease.
PubMed2020-08-2553 citations
Abatacept Is Effective for Gvhd Prophylaxis after Unrelated Donor Stem Cell Transplantation (URD SCT) for Severe Sickle Cell Disease (SCD)
Blood2019-11-131 citations